Q4 Earnings Forecast for ELEV Issued By William Blair

Elevation Oncology, Inc. (NASDAQ:ELEV) – William Blair issued their Q4 2024 EPS estimates for shares of Elevation Oncology in a research note issued on Tuesday, January 14th. William Blair analyst A. Hsieh forecasts that the company will post earnings of ($0.18) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share.

Several other equities analysts also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Elevation Oncology in a research report on Tuesday. Stephens reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Elevation Oncology in a research report on Friday, December 6th. Finally, JMP Securities reissued a “market outperform” rating and issued a $7.00 target price on shares of Elevation Oncology in a report on Thursday, December 19th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Elevation Oncology presently has an average rating of “Buy” and an average price target of $7.20.

Elevation Oncology Trading Up 6.2 %

Shares of ELEV stock opened at $0.71 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77. The company has a market cap of $42.05 million, a price-to-earnings ratio of -0.87 and a beta of 1.28. Elevation Oncology has a 1 year low of $0.50 and a 1 year high of $5.83. The firm has a fifty day moving average price of $0.64 and a 200-day moving average price of $1.01.

Elevation Oncology (NASDAQ:ELEV) last announced its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.02).

Institutional Trading of Elevation Oncology

Several institutional investors have recently made changes to their positions in ELEV. XTX Topco Ltd bought a new position in Elevation Oncology in the 2nd quarter worth approximately $103,000. SG Americas Securities LLC purchased a new position in shares of Elevation Oncology in the third quarter worth $28,000. American Century Companies Inc. boosted its position in shares of Elevation Oncology by 55.7% during the second quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock worth $133,000 after acquiring an additional 17,602 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Elevation Oncology by 175.9% during the third quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock valued at $37,000 after acquiring an additional 39,101 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Elevation Oncology in the 2nd quarter valued at $175,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.